Serious infection rates (safety population)
| Placebo+MTX (n=207) | Ocrelizumab (200 mg×2)+MTX (n=196) | Ocrelizumab (500 mg×2)+MTX (n=202) | |
|---|---|---|---|
| Total patient-years | 201.1 | 190.7 | 196.7 |
| Serious infections | 6 | 5 | 14 |
| Serious infections/100 patient-years | 3.0 | 2.6 | 7.1 |
| 95% CI | 1.09 to 6.49 | 0.85 to 6.12 | 3.89 to 11.94 |
Multiple occurrences of the same event in one individual are counted multiple times.
MTX, methotrexate.